Nurix Therapeutics, Inc. (NRIX) AI Stock Summary

Snapshot

Nurix is a clinical-stage biotech that burns cash aggressively to fund research. FY 2025 revenue was $84 million, up 54% year-over-year, but the company lost $264.5 million in net income. That loss is driven by heavy investment, with R&D spending of $308.2M (367% of revenue). The company had $592.9 million in cash at year-end, but its free cash flow burn of $263.5 million suggests a runway of roughly 22 months without new funding. The recent $700 million upfront payment from Roche effectively resets the cash runway to several years. The stock trades at a negative P/E of -5.48, reflecting its unprofitable status, and sits in the middle of its 52-week range. Share count grew 29% last year, a sign of dilution used to fund operations.

What's Happening Right Now

• Mon 8th Jun '26 · Partnership: Nurix signed a global deal with Roche to co-develop bexobrutideg, receiving a $700 million upfront payment and up to $2.3 billion in milestones.
• Thu 14th May '26 · Clinical Data: New preclinical and Phase 1 data showed bexobrutideg achieves complete BTK degradation in blood and skin, supporting expansion into immunology.
• Wed 8th Apr '26 · Earnings: Q1 2026 results showed a revenue miss of $6.3 million against a $14.3 million estimate, alongside an EPS miss.

Ownership

Institutions hold 100.0% of the shares, while insiders hold 0.2%.

Bottom Line

Nurix is a classic pre-revenue biotech story: high risk, high reward, and heavy cash burn. The business is not profitable and does not expect to be for years, but the recent partnership with Roche is a massive positive signal. The $700 million upfront payment solves the immediate cash crunch and validates the science behind their lead drug. The stock is not cheap, but it is not priced for perfection either. A reader should focus on the upcoming clinical trial results for bexobrutideg, as the stock's future value depends entirely on whether that drug works and gets approved.